ClinicalTrials.gg

Program

CRB-913

A development code.

Its studies are mostly in Obesity, led by Corbus Pharmaceuticals.

Furthest: phase 1, since Dec 16, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Corbus Pharmaceuticals10 open or runningphase 1since Dec 16, 2025Dec 16, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2025First study: phase 1 study in ObesityFirst studyNCT07310901 · 254 enrolled · United States

TargetBeta

CNR1 →read by rule
“CRB-913 is a novel cannabinoid receptor type 1 (CB1) inverse agonist (CB1-IA) that is being developed for once-daily treatment of obesity.”study text, by rule · the study

Other programs on CNR1

ProgramCompanyFurthest phaseStudies
CannabidiolruleJazz Pharmaceuticalsphase 468
RimonabantruleSanofiphase 338
DronabinolruleJazz Pharmaceuticalsphase 320

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07310901Obesity · United States1CompletedAug 3, 2026254

How it is read

Names in the registry

  • “CRB-913”, 1 entry

Codes read as this program: CRB913.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.